Tuesday 18th December 2007

ImpediMed Limited wishes to advise that CEO Greg Brown is delivering the attached roadshow presentation to various institutional investors and broking houses during the remainder of this week.

The presentation provides an introduction to the company.

[Signature]

Phil Auckland
CFO & Company Secretary
ImpediMed overview

- Australian company – ASX Listed
- Listing raised $18 million
- Acquired San Diego based BIS company Xitron Technologies
- Professional investors - Versant ventures (Menlo Park California), Starfish ventures
- Internationally experienced management team – Digene Corp., Roche, & AMCC
- ISO 13485 2003 std Quality system
Lymphoedema - what is it?

Lymphatic system
- Transports and filters waste products of the cells
- It is the primary component of the immune system

Lymphoedema - Primary and secondary
- Breakdown of the lymphatics where transport capacity falls
- Can be primary (genetic) or secondary - often a complication of cancer treatment – surgery, radiotherapy, chemotherapy
- Painful, lifelong condition - no cure, adversely affects quality-of-life
Current care and diagnosis

- Current diagnosis and standard of care
  - Lymphoedema is a chronic debilitating disease that is frequently misdiagnosed, treated too late, or not treated at all
    J Nucl Med 03; 44:43–57
  - Patients often suffer in silence when their primary care physician or surgeon suggests that the problem is mild & little can be done
    J Nucl Med 03; 44:43–57
Lympohedema prevalence

- Approximately 10 million Americans, as an example, have lymphoedema secondary to breast and pelvic cancer therapy, recurrent infections, injuries, or vascular surgery.
  

- 32 percent of women aged 45 years and younger treated for breast cancer had persistent swelling in the hand and/or arm 3 years after surgery. The incidence of episodic swelling was 54%.
  
  US National Cancer Institute Newsletter April 2007

- Lower extremity lymphoedema resulting from treatment of pelvic cancer also occurs. Reported frequency of secondary leg lymphoedema ranges from 10% to 49%.
  
Why ImpediMed is well positioned

Targeting prevention of lymphoedema progression
1. Technology validation

- **BIS technology measures the extra-cellular fluid of limbs directly**

- Over 10 years of peer reviewed publications since 1996 demonstrating early detection, clinical assessment and risk assessment of Lymphoedema

- First bioimpedance technology to receive FDA clearance for the clinical assessment of unilateral arm lymphoedema
2. Commercial and regulatory status

- **XCA**
  - First FDA cleared medical device for the clinical assessment for uni-lateral lymphoedema of the arm
  - Single low frequency - patented
  - Uni-lateral arm only - control limb
  - Distribution building
  - Longer term homecare product

- **SFB 7**
  - BIS research device - not a clinical device
  - FDA submissions planned- for the clinical assessment for uni- & bi-lateral lymphoedema of the arm and legs 2008
  - Over 10 years of peer reviewed science since 1996 built on BIS technology
  - Distribution building
2. Commercial and regulatory status (continued)

- **SFB 9**
  - Clinical routine device
  - FDA submission for the clinical assessment for uni- & bi-lateral lymphoedema of the arm and legs - targeting 510K specials to the SFB7
  - Prototype in late 2008 for trials
  - Target commercial launch in 2009
  - Locked in revenue streams

*Picture - concept only*
3. Building clinical data supporting early detection

- Prospective NIH/NCI trial in breast cancer patients started 2000 and completed end of 2006
- The 5 year study took measurements using a standard volumetric technique (Perometer) from baseline
- Lymphoedema where detected early- 2 week regime of compression sleeve
- Early detection, early intervention arm - no woman progressed to develop chronic (Stage II or III) lymphoedema over the course of the study
- Numerous publications proposed
  - Clinical outcome publication
  - Health economic analysis
  - Quality of life analysis
4. ImpediMed targeting proposed new clinical paradigm: pre-emptive care

Surgeon / Oncologist
Risk Assessment
2 x Misc code

Cancer Diagnosis
Breast
Pelvic
Lymphoma
Melanoma

Surgeon Baselines patient
2 x Misc code

3-6 months after intervention

High Risk Patient - Homecare

Low Risk Patient - Provider Care

$18,000 SFB9 Device

$500 to $1000 Device

$120 to $240/ year/ homecare patient in consumables

Healthy lifestyle
5. Reimbursement - targeting miscellaneous codes until category one code is available

<table>
<thead>
<tr>
<th>Code</th>
<th>Major Title</th>
<th>Minor Titles</th>
<th>Excludes</th>
</tr>
</thead>
<tbody>
<tr>
<td>457</td>
<td>Noninfectious disorders of lymphatic channels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>457.0</td>
<td>Postmastectomy lymphedema syndrome</td>
<td>Elephantiasis (due to mastectomy) Obliteration of lymphatic vessel (Mastectomy)</td>
<td></td>
</tr>
<tr>
<td>457.1</td>
<td>Other Lymphedema</td>
<td>Elephantiasis (nonfilarial) NOS Lymphangiectasis Lymphedema: acquired (chronic), praecox, secondary</td>
<td>Elephantiasis (nonfilarial): congenital (757.0) eyelid (374.83) vulva (624.8)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>97001</td>
<td>Physical therapy evaluation</td>
<td>US$63.43</td>
</tr>
<tr>
<td>97140</td>
<td>Occupational therapy evaluation</td>
<td>US$62.90</td>
</tr>
<tr>
<td>97530</td>
<td>Physical therapy re-evaluation</td>
<td>US$29.56</td>
</tr>
</tbody>
</table>

- With Miscellaneous codes for Surgeons for BIS bioimpedance reading
- With Miscellaneous codes for Oncologists for BIS bioimpedance reading
- With Miscellaneous codes for Therapist for BIS bioimpedance reading
6. Strategic partnerships

- Decongestive therapy schools (CTS)
  - Norton’s and Vodder (global)
  - Estimated 3000 to 5000 specialist therapists in the US
- Compression sleeve suppliers (global)
  - Targeting distribution partners
- Physicians and aged care (US only)
  - Targeting distribution partners
- Surgeons / oncologists (Global)
  - Targeting US companies with managed care, surgeon and oncologist sales team
- European Diagnostic Network EDN (Europe)
  - Launching European effort
7. Estimated market potential - significant potential

<table>
<thead>
<tr>
<th>Summary - US lymphoedema</th>
<th>Total Device Market</th>
<th>Annual Consumable Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast Cancer - Home devices &amp; consumables</td>
<td>$493</td>
<td>$142</td>
</tr>
<tr>
<td>Breast Cancer - Consumables provider market</td>
<td></td>
<td>$71</td>
</tr>
<tr>
<td>Pelvic Cancers - Home devices &amp; consumables</td>
<td>$801</td>
<td>$231</td>
</tr>
<tr>
<td>Pelvic Cancers - Consumables provider market</td>
<td></td>
<td>$82</td>
</tr>
<tr>
<td>Clinical Device Market</td>
<td>$3,138</td>
<td></td>
</tr>
<tr>
<td>Total lymphedema</td>
<td>$4,432</td>
<td>$527</td>
</tr>
</tbody>
</table>

Table in Millions of USD - assumes 100% adoption of new clinical approach to Lymphoedema
Other ImpediMed opportunities

Hydration and other imaging applications
ImpediMed hydration/body composition market targets

Cachexia market
- Chemo
- Elderly
- AIDS
- Dialysis

Research markets
- New drug development
- Nutritional studies

Imaging markets
- DEXA suppliers
- IR imaging
- MRI

Dialysis market
- Dry mass market
- Fresenius relationship

Hydration Market
- $1.0 B device
- $0.1 B consumables

Healthy lifestyle
Targeting diagnosis of metabolic disorder syndrome

- Contracted research with a European university
- Visceral / subcutaneous abdominal fat differentiation
- BIS application – imaging modality to quantitate the difference in abdominal fatness
- Will be a 1 minute reading with proprietary abdominal electrode – expanding SFB7 and SFB9 utility
- Reimbursement presently for CT scan of $460 (CPT 74170) to MRI $705 (CPT 74182)
- Associated with metabolic disorder syndrome
  - heart disease
  - hypertension
  - insulin resistance
  - type II diabetes mellitus
# Senior Management

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Company</th>
<th>Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Brown</td>
<td>CEO</td>
<td>Digene - US/Europe</td>
<td>6 Yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Digene - Switzerland/USA (NY)</td>
<td>4 Yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Baxter - Australia/Germany/UK</td>
<td>9 Yrs</td>
</tr>
<tr>
<td>Phil Auckland</td>
<td>CFO/COO</td>
<td>PanBio Ltd</td>
<td>7 Yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Motor Ind/Dist’n</td>
<td>10 Yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Corp Finance</td>
<td>6 Yrs</td>
</tr>
<tr>
<td>Jack Butler</td>
<td>VP Sales and Marketing US</td>
<td>Digene</td>
<td>5 Yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roche</td>
<td>12 Yrs</td>
</tr>
<tr>
<td>Steve Smith</td>
<td>VP Operations</td>
<td>AMCC</td>
<td>5 Yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ST Microelectronics</td>
<td>5 Yrs</td>
</tr>
</tbody>
</table>
Board of Directors

Mel Bridges BSc FAICD – Non Executive Chairman
Chairman of Alchemia (ASX:ACL)
CEO and founder of Panbio Limited (ASX:PBO) until 2003; Founder and MD of Pacific Dx, sold to Baxter
Director of Delvtech. Previously Chairman of Peptech (ASX:PTD)

Martin Kriewaldt BA LLB (Hons) FAICD – Non Executive Director
Director of Peptech Limited (ASX:PTD), Suncorp-Metway Ltd (ASX:SUN), Oil Search Limited (ASX: OSH),
GWA International (ASX: GWT) and Campbell Brothers Limited (ASX:CPB) & Chair of Rem Comm

Cherrell Hirst AO MBBS FAICD – Non Executive Director
Medical doctor and a former practitioner in breast cancer diagnosis.
Director of Suncorp-Metway Ltd (ASX:SUN), QBF (also acting CEO), Peplin, Avant ML & IL, MBF Australia
Previously Chancellor of QUT 1994 – 2004

Jim Hazel – BEc FFin FAICD – Non Executive Director
Extensive banking career including Chief General Manager of Adelaide Bank Limited
Until recently MD of ASX-listed retirement village and aged care operation.
Chairman of Elders Rural Bank Limited, Chairman of Becton Living Pty Ltd and Director of Terramin
Australia Limited (ASX:TZN). Previous NED roles include SA Govt Financing Authority, Peptech Limited, St
Andrews Hospital Inc and Tourism SA

Michael Panaccio BSc (Hons) MBA PhD FAICD – Non Executive Director
Co-founder and Investment Principal of Starfish Ventures, Chairman of the Australian Biotechnology
Advisory Committee. More than 10 years with multinational pharmaceutical companies and work with
Nomura/JAFCO Investment (Asia) Limited
Risk management - key risks

- Risk to Secondary Lymphoedema Opportunity
  - Major clinical trials
  - Bilateral lymphoedema approaches

- Reimbursement & Regulatory Strategies
  - Securing necessary further FDA Approvals
  - Gaining reimbursement coding and coverage

- Intellectual Property
  - Ability to protect position
  - Competitor Challenges to IP

- Advancing technology
  - Competitor threat of new technology approaches
  - Supply threat - key component redesign

- Product Liability
  - Liability risks that are inherent in research and development, preclinical studies, clinical trials, manufacturing and the use as a medical device for diagnosing/monitoring conditions
Conclusion

- Business commercializing product range
- Market entry strategy facilitated by:
  - Building global distribution
  - Regulatory – first cleared device for Lymphoedema
  - Reimbursement - applying for category one CPT code
  - Building higher claims to limit competition and expand reimbursement
  - Commercial partnerships
  - Clinical trial programs
- Experienced team and Board